These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25700025)

  • 21. Role of human CD4 D1D2 domain in HIV-1 infection.
    Li L; Shi X; Lu Q; Zhang S; Wang X; Jiang X; Liu Y; Wang G; Zhu W; Lei R; Wu H
    Immunol Invest; 2013; 42(2):106-21. PubMed ID: 23252862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.
    Malbec M; Porrot F; Rua R; Horwitz J; Klein F; Halper-Stromberg A; Scheid JF; Eden C; Mouquet H; Nussenzweig MC; Schwartz O
    J Exp Med; 2013 Dec; 210(13):2813-21. PubMed ID: 24277152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.
    Braibant M; Gong EY; Plantier JC; Moreau T; Alessandri E; Simon F; Barin F
    AIDS; 2013 May; 27(8):1239-44. PubMed ID: 23343910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.
    Griffith SA; McCoy LE
    Front Immunol; 2021; 12():708227. PubMed ID: 34737737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and characterisation of replicating foamy viral vectors expressing HIV-1 epitopes recognised by broadly neutralising antibodies.
    Mühle M; Hoffmann K; Löchelt M; Denner J
    Antiviral Res; 2013 Nov; 100(2):314-20. PubMed ID: 24055836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration.
    Zhu L; Huang B; Wang X; Ni F; Ao M; Wang R; Zheng B; Chen C; Xue J; Zhu L; Yang C; Shi L; Geng S; Hu J; Yang M; Zhang D; Yang P; Li M; Li Y; Hu Q; Ye S; Zheng P; Wei H; Wu Z; Zhang L; Wang Y; Liu Y; Wu X
    Nat Commun; 2024 Aug; 15(1):6961. PubMed ID: 39138183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immune Effects and Mechanisms of HIV-specific Antibodies Against Viral Infection].
    Su B; Li L; Mou D; Moog C; Wu H; Zhang T
    Bing Du Xue Bao; 2016 Nov; 32(6):830-8. PubMed ID: 30004659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants.
    Moore CM; Grandits M; Grünwald-Gruber C; Altmann F; Kotouckova M; Teh AY; Ma JK
    Retrovirology; 2021 Jun; 18(1):17. PubMed ID: 34183026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placental Hofbauer cells assemble and sequester HIV-1 in tetraspanin-positive compartments that are accessible to broadly neutralizing antibodies.
    Johnson EL; Chu H; Byrareddy SN; Spearman P; Chakraborty R
    J Int AIDS Soc; 2015; 18(1):19385. PubMed ID: 25623930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?
    Ananworanich J; McSteen B; Robb ML
    Curr Opin HIV AIDS; 2015 May; 10(3):198-206. PubMed ID: 25700203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.
    Halper-Stromberg A; Nussenzweig MC
    J Clin Invest; 2016 Feb; 126(2):415-23. PubMed ID: 26752643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 antibodies in prevention of transmission.
    Barin F; Braibant M
    Curr Opin HIV AIDS; 2019 Jul; 14(4):273-278. PubMed ID: 30973417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.
    Abela IA; Berlinger L; Schanz M; Reynell L; Günthard HF; Rusert P; Trkola A
    PLoS Pathog; 2012; 8(4):e1002634. PubMed ID: 22496655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
    Moshoette T; Papathanasopoulos MA; Killick MA
    Virol J; 2022 Sep; 19(1):143. PubMed ID: 36071449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
    Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
    Front Immunol; 2022; 13():893648. PubMed ID: 35651621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.
    Zhang B; Gorman J; Kwon YD; Pegu A; Chao CW; Liu T; Asokan M; Bender MF; Bylund T; Damron L; Gollapudi D; Lei P; Li Y; Liu C; Louder MK; McKee K; Olia AS; Rawi R; Schön A; Wang S; Yang ES; Yang Y; Carlton K; Doria-Rose NA; Shapiro L; Seaman MS; Mascola JR; Kwong PD
    MAbs; 2023; 15(1):2165390. PubMed ID: 36729903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elimination of HIV-1-infected cells by broadly neutralizing antibodies.
    Bruel T; Guivel-Benhassine F; Amraoui S; Malbec M; Richard L; Bourdic K; Donahue DA; Lorin V; Casartelli N; Noël N; Lambotte O; Mouquet H; Schwartz O
    Nat Commun; 2016 Mar; 7():10844. PubMed ID: 26936020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications.
    Singh AA; Pooe O; Kwezi L; Lotter-Stark T; Stoychev SH; Alexandra K; Gerber I; Bhiman JN; Vorster J; Pauly M; Zeitlin L; Whaley K; Mach L; Steinkellner H; Morris L; Tsekoa TL; Chikwamba R
    Sci Rep; 2020 Apr; 10(1):6201. PubMed ID: 32277089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.